ABUS

Over the past six months, Arbutus Biopharma experienced several significant stock events. In April 2026, imdusiran received FDA Fast-Track designation, followed by an agreement with the FDA on its Phase 2b trial design in May. The company reported Q2 2026 financial results in August, showing decreased revenues of $1.0 million compared to $10.7 million in Q2 2025, and a net loss of $5.1 million versus a net income of $2.5 million in Q2 2025. A major event in July 2026 was receiving $178.4 million from a settlement with Moderna, leading to an announced intent to return capital to shareholders and the commencement of a US$230 million modified "Dutch Auction" tender offer in August, scheduled to expire on September 29, 2026. Arbutus also initiated international patent infringement actions against Pfizer and BioNTech in July, was dropped from the Russell 2500 Value Benchmark, and announced changes in its CFO and CEO. Additionally, in July 2026, Arbutus and Vaccitech signed a clinical trial collaboration agreement for an RNAi therapeutic plus immunotherapeutic to treat chronic hepatitis B virus (HBV) infection.